R&D Taking the microbiome seriously, with Sam Possemiers pharmaphorum catches up with MRM Health founder and CEO Sam Possemiers at LSX 2026.
News MHRA clarifies UK position on microbiome-based medicines The MHRA has published its position paper clarifying how microbiome-based medicines can be made available for patients in the UK.
Oncology ASCO 2026: Powerful evidence for the microbiome in oncology,... Can the state of someone’s gut microbiome – the balance of good and bad bacteria in their digestive tract – affect their response to cancer immunother
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
News Vedanta's microbiome therapy for IBD disappoints Vedanta's microbiome therapy for ulcerative colitis has failed a phase 2 trial and will be shelved, prompting a 20% cut in workforce.
News EnteroBiotix cues up larger trial of microbiome IBS therapy EnteroBiotix has reported phase 2a proof-of-concept data for its therapy for irritable bowel syndrome (IBS) based on gut microbiome species.
Oncology On looking to a future multiomics approach for CDx, with Jan... The pharmaphorum podcast caught up with Jane Li, VP and general manager for companion diagnostics at Thermo Fisher Scientific, following ESMO 2026.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.